Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 2 May 2022 |
| Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 29 April 2022 | 2 May 2022 |
| Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022 | 29 Apr 2022 |
| Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022 | 29 Apr 2022 |
| Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022 | 29 Apr 2022 |